News

Moderna targets $4.2B cash cost reduction by 2027 amid expanded FDA approvals and $400M in accelerated 2025 savings
Discover key takeaways from Moderna's Q2 2025 earnings call, including FDA approvals, cost reductions, pipeline strategies, and financial updates.
WillScot Holdings Corporation (NASDAQ:WSC) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript July 31, 2025 WillScot Holdings Corporation misses on earnings expectations. Reported EPS is ...
WillScot outlines $500M–$550M free cash flow target for 2025 as large-project demand persists
Explore Q2 2025 earnings insights for WillScot (WSC): robust free cash flow, margin expansion, enterprise growth, and strategic investments amid ...
Treasury & Risk20h
New Cash Leadership Office Builds a Working Capital Culture at BMS
Congratulations to Bristol Myers Squibb on winning the 2025 Gold Alexander Hamilton Award in Working Capital Management!